Abstract
Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.
Keywords: COVID-19; Disease modifying treatments; Humoral immunity; IgG antibody; Multiple sclerosis; Vaccination.
【저자키워드】 COVID-19, vaccination, multiple sclerosis, Humoral immunity, IgG antibody, Disease modifying treatments, 【초록키워드】 Treatment, IgG, Vaccine, immune response, vaccination, cross-sectional, Natalizumab, COVID-19 vaccination, response, Patient, fingolimod, Ocrelizumab, Cladribine, Alemtuzumab, IgG response, dimethyl fumarate, Teriflunomide, healthy subjects, help, Multiple, treated patients, treated, demonstrated, healthy subject, Appropriate, 【제목키워드】 COVID19, immune response, cross-sectional, Patient,